Twist Bioscience Corporation

NasdaqGS:TWST Stock Report

Market Cap: US$1.7b

Twist Bioscience Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Emily Leproust

Chief executive officer

US$8.0m

Total compensation

CEO salary percentage8.6%
CEO tenure11yrs
CEO ownership0.4%
Management average tenure2.9yrs
Board average tenure7.4yrs

Recent management updates

Here's Why Shareholders May Want To Be Cautious With Increasing Twist Bioscience Corporation's (NASDAQ:TWST) CEO Pay Packet

Jan 31
Here's Why Shareholders May Want To Be Cautious With Increasing Twist Bioscience Corporation's (NASDAQ:TWST) CEO Pay Packet

Recent updates

Twist Bioscience Corporation (NASDAQ:TWST) Surges 26% Yet Its Low P/S Is No Reason For Excitement

Feb 27
Twist Bioscience Corporation (NASDAQ:TWST) Surges 26% Yet Its Low P/S Is No Reason For Excitement

Twist Bioscience: Strong Performance In A Soft Market

Feb 07

Here's Why Shareholders May Want To Be Cautious With Increasing Twist Bioscience Corporation's (NASDAQ:TWST) CEO Pay Packet

Jan 31
Here's Why Shareholders May Want To Be Cautious With Increasing Twist Bioscience Corporation's (NASDAQ:TWST) CEO Pay Packet

We're Not Very Worried About Twist Bioscience's (NASDAQ:TWST) Cash Burn Rate

Jan 22
We're Not Very Worried About Twist Bioscience's (NASDAQ:TWST) Cash Burn Rate

Twist Bioscience Corporation's (NASDAQ:TWST) Price Is Right But Growth Is Lacking After Shares Rocket 44%

Dec 18
Twist Bioscience Corporation's (NASDAQ:TWST) Price Is Right But Growth Is Lacking After Shares Rocket 44%

Twist Bioscience (NASDAQ:TWST) Is In A Good Position To Deliver On Growth Plans

Oct 05
Twist Bioscience (NASDAQ:TWST) Is In A Good Position To Deliver On Growth Plans

We Think Twist Bioscience (NASDAQ:TWST) Can Afford To Drive Business Growth

Jul 07
We Think Twist Bioscience (NASDAQ:TWST) Can Afford To Drive Business Growth

Twist Biosciences collaborates with Enzolytics on monoclonal antibodies for viruses

Sep 16

Twist Bioscience: DNA Synthesis Leader Appealing 'Picks And Shovels' Play

Sep 02

Twist Bioscience: DNA Synthesis Leader Is Just Getting Started

Aug 08

Twist Bioscience/ Biotia sequencing assay granted FDA nod to detect COVID variants

Aug 02

Twist Biosciences to work with DNAnexus on sequencing-based diagnostic tests

Jul 13

Twist Bioscience, Ildong team up to discover antibodies for cancer therapies

Jun 30

Twist Bioscience: A First Take

May 26

CEO Compensation Analysis

How has Emily Leproust's remuneration changed compared to Twist Bioscience's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-US$206m

Sep 30 2023US$8mUS$685k

-US$205m

Jun 30 2023n/an/a

-US$209m

Mar 31 2023n/an/a

-US$213m

Dec 31 2022n/an/a

-US$214m

Sep 30 2022US$6mUS$665k

-US$218m

Jun 30 2022n/an/a

-US$208m

Mar 31 2022n/an/a

-US$188m

Dec 31 2021n/an/a

-US$165m

Sep 30 2021US$1mUS$590k

-US$152m

Jun 30 2021n/an/a

-US$135m

Mar 31 2021n/an/a

-US$123m

Dec 31 2020n/an/a

-US$117m

Sep 30 2020US$7mUS$519k

-US$140m

Jun 30 2020n/an/a

-US$147m

Mar 31 2020n/an/a

-US$147m

Dec 31 2019n/an/a

-US$141m

Sep 30 2019US$8mUS$477k

-US$108m

Jun 30 2019n/an/a

-US$96m

Mar 31 2019n/an/a

-US$86m

Dec 31 2018n/an/a

-US$77m

Sep 30 2018US$525kUS$362k

-US$71m

Jun 30 2018n/an/a

-US$68m

Sep 30 2017US$2mUS$340k

-US$59m

Compensation vs Market: Emily's total compensation ($USD8.00M) is above average for companies of similar size in the US market ($USD5.57M).

Compensation vs Earnings: Emily's compensation has increased whilst the company is unprofitable.

CEO

Emily Leproust (50 yo)

11yrs

Tenure

US$7,998,637

Compensation

Dr. Emily Marine Leproust, Ph.D. serves as Independent Director at CM Life Sciences, Inc. since September 2, 2020. She serves as an Independent Director at GeneDx Holdings Corp. (formerly known as Sema4 Ho...

Leadership Team

NamePositionTenureCompensationOwnership
Emily Leproust
Co-Founder11yrsUS$8.00m0.36%
$ 6.1m
Patrick Finn
President & COO1.5yrsUS$5.23m0.078%
$ 1.3m
Paula Green
Senior Vice President of Human Resources8.1yrsUS$2.49m0.030%
$ 513.5k
William Banyai
Senior VP of Advanced Development4.3yrsUS$2.82m0.44%
$ 7.6m
Adam Laponis
Chief Financial Officerless than a yearno data0.0017%
$ 29.6k
Robert Werner
VP & Chief Accounting Officerless than a yearno data0.0017%
$ 28.3k
Siyuan Chen
Chief Technology Officer3.2yrsno datano data
Aaron Sato
Chief Scientific Officer3.2yrsno datano data
Chet Gandhi
Chief Information Officerless than a yearno datano data
Dennis Cho
Senior VP2.6yrsUS$1.96m0.041%
$ 704.3k
Angela Bitting
Chief ESG Officer & Senior VP of Corporate Affairs3.2yrsno datano data
Tracey Mullen
Senior Vice President of Biopharma1.5yrsno datano data

2.9yrs

Average Tenure

51yo

Average Age

Experienced Management: TWST's management team is considered experienced (2.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Emily Leproust
Co-Founder11yrsUS$8.00m0.36%
$ 6.1m
William Banyai
Senior VP of Advanced Development11yrsUS$2.82m0.44%
$ 7.6m
Keith Crandell
Independent Director10.5yrsUS$272.49k0.16%
$ 2.8m
Robert Chess
Lead Independent Director9.8yrsUS$303.98k0.11%
$ 1.9m
Nelson Chan
Independent Director4.9yrsUS$284.99k0.031%
$ 526.3k
Robert Ragusa
Independent Director7.4yrsUS$271.34k0.024%
$ 400.5k
Jan Johannessen
Independent Director5.5yrsUS$284.99k0.020%
$ 342.1k
Melissa Starovasnik
Independent Director2.7yrsUS$276.61k0.019%
$ 320.5k
Xiaoying Mai
Independent Director5.8yrsUS$269.99k0.044%
$ 743.4k

7.4yrs

Average Tenure

63yo

Average Age

Experienced Board: TWST's board of directors are considered experienced (7.4 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.